Interestingly, recent studies revealed that both IFN-based [27] and IFN-free therapies [28] improved liver stiffness in HIV/HCV coinfected patients, suggesting liver fibrosis regression and a reduction in portal pressure [29]. This evidence concerns the gene IFNA1 and Hepatic fibrosis.